Bio-Path Now Covered by Analysts at StockNews.com
| BPTH Stock | USD 1.07 0.02 1.83% |
Under 61% of Bio Path's investor base is looking to short. The analysis of the overall investor sentiment regarding Bio Path Holdings suggests that many traders are alarmed. Bio Path's investing sentiment shows overall attitude of investors towards Bio Path Holdings.
Bio |
StockNews.com initiated coverage on shares of Bio-Path in a research report report published on Friday. The firm issued a sell rating on the stock. Bio-Path Stock Performance NASDAQBPTH opened at 1.16 on Friday. The firm has a 50-day simple moving average of 0.90 and a 200-day simple moving average of 1.20.
Read at thelincolnianonline.com
 |
Bio Path Fundamental Analysis
We analyze Bio Path's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bio Path using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bio Path based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash Per Share
Cash Per Share Comparative Analysis
Bio Path is currently under evaluation in cash per share category among its peers. Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Bio Path Holdings Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Bio Path stock to make a market-neutral strategy. Peer analysis of Bio Path could also be used in its relative valuation, which is a method of valuing Bio Path by comparing valuation metrics with similar companies.
Peers
Bio Path Related Equities
| ACHV | Achieve Life | 5.07 | ||||
| AKTX | Akari Therapeutics | 2.17 | ||||
| MBRX | Moleculin Biotech | 1.13 | ||||
| PULM | Pulmatrix | 0.48 | ||||
| ALRN | Aileron Therapeutics | 1.91 | ||||
| CRNX | Crinetics Pharmaceuticals | 2.12 | ||||
| BNTC | Benitec Biopharma | 3.05 | ||||
| NXTC | NextCure | 3.26 | ||||
| CAPR | Capricor Therapeutics | 5.20 |
Complementary Tools for Bio Stock analysis
When running Bio Path's price analysis, check to measure Bio Path's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bio Path is operating at the current time. Most of Bio Path's value examination focuses on studying past and present price action to predict the probability of Bio Path's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bio Path's price. Additionally, you may evaluate how the addition of Bio Path to your portfolios can decrease your overall portfolio volatility.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |